Personally, I see the magic path to boosting Faron’s credibility and market cap as:
- Initiating the Bexera study with a precise start date
- Neutralizing financing risk without causing dilution, e.g., a regional licensing agreement or a Phase 3 cost-sharing partnership that would bring in upfront cash
- Clarity regarding recruitment and milestones, along with partner-led options, rather than Faron spreading its focus everywhere—keeping it on the primary project instead
Stories might resonate with retail investors like us, but institutions are looking for reliability and execution.
With these, the situation could improve in terms of market valuation as well